Markel Launches Travel Reimbursement Scheme to Boost Rare Disease Trial Enrollment
核心洞察
Markel Insurance (搜索) has introduced a travel cover enhancement that reimburses eligible travel-related expenses for participants in international rare disease clinical trials.
The scheme is purchased by trial sponsors and developed in response to feedback from life science companies and brokers seeking to support participants travelling internationally.
Suvoda (搜索) research found 57% of prospective trial participants rated financial barriers as very important when deciding whether to enroll, driving low enrollment and trial terminations.
Markel Insurance (搜索) has launched a reimbursement scheme designed to boost enrollment in international trials evaluating rare disease therapies, addressing a persistent barrier that sponsors have struggled to overcome. The enhancement is purchased by trial sponsors and reimburses eligible travel-related expenses for approved participant travel to and from clinical trial sites.
The product was developed in response to feedback from life science companies and brokers seeking a way to help trial sponsors support eligible participants who need to travel internationally to take part in rare disease clinical trials. Rare disease trials often struggle with patient recruitment, with small and dispersed populations cited as a contributing factor.
Financial Barriers Drive Low Enrollment
Research published by Suvoda (搜索) found that 57% of prospective clinical trial participants considered financial barriers "very important" when deciding whether to enroll. This contributes to low enrollment, which continues to be the main reason for trial terminations globally.
Because of the nature of rare disease patient populations, trial participants may need to travel internationally to access specialist research sites, meaning costs are often extremely high. Beyond expense, many patients may struggle to obtain travel insurance due to their rare disease.
Under Markel's scheme, patients registered under the policy who have been medically assessed as fit to travel by their doctor can access 24-hour assistance from global healthcare services provider Healix (搜索), which includes necessary medical care while travelling. The scheme allows sponsors to be reimbursed without directly paying participants.
Underwriter Cites Geographic Dispersion of Patients
Robert Hannaford, senior life science underwriter at Markel International, said: "People living with a rare disease may need to travel considerable distances to access specialist clinical trials. In rare-disease research, eligible participants and specialist trial sites are not always in the same country.
"When patient populations are geographically dispersed, participation can depend on a person's ability to travel, not simply their willingness to take part. This enhancement is designed to help trial sponsors support eligible participants who need to make those journeys by reimbursing eligible travel-related expenses and providing access to assistance services while travelling, subject to policy terms and conditions."
Alternative Recruitment Strategies and Regulatory Pathways
Companies are turning to real-world data (RWD) and natural history data, as well as digital twins, to try to bolster recruitment in rare disease trials. While these tactics do improve recruitment challenges by creating virtual control arms, recruitment remains a challenge.
The US administration has introduced a variety of pathways for research, including the Rare Disease Evidence Pathway (RDEP), the Plausible Mechanism Pathway and the Innovative Designs for Clinical Trials of Cellular and Gene Therapy Products in Small Populations, to assist sponsors in designing alternative trials powered for lower recruitment. The US administration has shown significant support for the development of rare diseases, as well as chronic diseases, spearheaded by US Health Secretary Robert F. Kennedy Jr., who himself suffers from the chronic disease spasmodic dysphonia (搜索).